Compare WOR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | GLPG |
|---|---|---|
| Founded | 1955 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.2B |
| IPO Year | 1994 | N/A |
| Metric | WOR | GLPG |
|---|---|---|
| Price | $55.67 | $33.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $59.67 | $36.00 |
| AVG Volume (30 Days) | ★ 139.7K | 73.7K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,153,762,000.00 | N/A |
| Revenue This Year | $17.70 | $1.73 |
| Revenue Next Year | $5.30 | $0.49 |
| P/E Ratio | $45.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.05 | $22.59 |
| 52 Week High | $70.91 | $37.78 |
| Indicator | WOR | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 47.49 |
| Support Level | $51.36 | $33.12 |
| Resistance Level | $56.48 | $33.95 |
| Average True Range (ATR) | 1.28 | 0.63 |
| MACD | -0.26 | -0.08 |
| Stochastic Oscillator | 10.02 | 24.43 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.